Quality of Life Assessment in Adult Patients With Attention-deficit/Hyperactivity Disorder Treated With Atomoxetine
- 1 December 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 26 (6), 648-652
- https://doi.org/10.1097/01.jcp.0000239797.21826.70
Abstract
Attention-deficit/hyperactivity disorder (ADHD) has its onset during childhood and is estimated to affect 3% to 7% of school-aged children. Unfortunately, the disorder frequently persists into adult life. The burden of this disorder is considerable and is often characterized by academic (or occupational) impairment and dysfunction within the family and society. Despite the existence of research demonstrating the effects of ADHD on certain aspects of life, the clinical trials of treatments for this disorder have focused primarily on efficacy and safety. Atomoxetine was approved in the United States in November 2002 for the treatment of ADHD in children, adolescents, and adults. The present study uses data from a clinical trial of atomoxetine in adult patients with ADHD that incorporated a measure of health-related quality of life (the Medical Outcomes Study 36-item short-form health survey [SF-36]) as part of the overall assessment of the success of this relatively new treatment. The primary outcome measure for ADHD symptoms was the Conners Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS) ADHD total symptom score. In agreement with previous studies, adult patients with ADHD treated with atomoxetine at typical doses showed significant amelioration of ADHD symptoms, as measured on the CAARS. At baseline, the measures of overall mental health (one aspect of quality of life) of adult patients with ADHD were below the average level, as measured on the SF-36. Treatment with atomoxetine significantly improved the measures of mental health and ameliorated the ADHD symptoms. In addition, the 2 measures were correlated. These data suggest that pharmacological intervention with atomoxetine not only ameliorates ADHD symptoms in adult patients but also improves their perceived quality of life.Keywords
This publication has 8 references indexed in Scilit:
- Safety and Tolerability of Once Versus Twice Daily Atomoxetine in Adults with ADHDAnnals of Clinical Psychiatry, 2006
- Long-Term, Open-Label Study of the Safety and Efficacy of Atomoxetine in Adults With Attention-Deficit/Hyperactivity DisorderBritish Journal of Psychology, 2005
- Improvement in Health-Related Quality of Life in Children with ADHDJournal of Developmental & Behavioral Pediatrics, 2004
- The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity DisorderJournal of Developmental & Behavioral Pediatrics, 2004
- Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesBiological Psychiatry, 2003
- YOUNG ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER: SUBTYPE DIFFERENCES IN COMORBIDITY, EDUCATIONAL, AND CLINICAL HISTORYThe Journal of Nervous and Mental Disease, 2002
- Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom TypeAmerican Journal of Psychiatry, 2000
- Driving-Related Risks and Outcomes of Attention Deficit Hyperactivity Disorder in Adolescents and Young Adults: A 3- to 5-Year Follow-up SurveyPEDIATRICS, 1993